Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by mol...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Hofman, Véronique, Lassalle, Sandra, Bence, Coraline, Long-Mira, Elodie, Nahon-Estève, Sacha, Heeke, Simon, Lespinet-Fabre, Virginie, Butori, Catherine, Ilié, Marius, Hofman, Paul
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2018
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5876645/
https://ncbi.nlm.nih.gov/pubmed/29534030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10030070
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky